Elanco Animal Health Incorporated

October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority

Elanco released October consumer research showing 93% of surveyed pet owners maintained or increased pet spending over the past three months, with the same share expecting to maintain or increase spending in the year ahead. The survey of 2,018 U.S. consumers found only 7% would cut pet health spending under economic pressure, well below dining out, travel, or subscriptions, and 38% of owners have shifted medication purchasing outside the vet clinic to omnichannel options. Management framed the data as confirming the resilience of its pet health business, though the release contains no new financial results or guidance.

•2d ago

Elanco Animal Health Reports Third Quarter 2026 Results

Elanco reported Q3 2026 revenue of $1.265 billion, up 11% year-over-year (9% organic constant currency), with adjusted EPS of $0.27 up 42% YoY and adjusted EBITDA of $243 million at a 19.5% margin. The company raised full-year guidance across the board — revenue to $5.155B-$5.18B, adjusted EBITDA to $1.05B-$1.065B (+17% at midpoint), and adjusted EPS to $1.17-$1.20 (+26% at midpoint) — while lifting its innovation revenue target to $1.275 billion. Growth was led by Pet Health (+14%) and innovation products: Zenrelia posted record revenue and a 7-point gain in U.S. JAK market share, while Credelio Quattro became Elanco's largest U.S. Pet Health brand with 9 points of share growth. Net leverage hit the 2.9x milestone early, unlocking accelerated capital allocation flexibility, and management reaffirmed a 2027 algorithm of mid-single digit revenue and low-double digit EPS growth.

•2d ago

Addressing Critical Health Needs Through Innovation

Elanco published a promotional update highlighting its animal-health R&D momentum, noting it has doubled blockbuster-potential pipeline projects since 2021, increased peak sales potential by 70%, and tripled project throughput. Between 2020 and 2025 the company launched 21 products exceeding $10 million in revenue, versus six in the prior five-year period, supported by new R&D facilities in Indianapolis and Bangalore opened in 2025. The release recaps recent launches including Befrena for canine dermatology, an improved Zenrelia label, Credelio Quattro, and a Credelio CAT EUA for New World screwworm.

•12d ago

More Than 2 Million Dogs Reach for Zen: Elanco Helps Veterinarians and Pet Owners Navigate Extended Allergy Season With Zenrelia(TM) (Ilunocitinib Tablets)

Elanco's Zenrelia (ilunocitinib tablets) has treated more than 2 million dogs across 48 countries, including the U.S., EU, UK, Brazil, Canada, Australia and Japan. Since its September 2024 U.S. launch, Zenrelia has shown 99% prescribing loyalty among surveyed U.S. veterinarians, and Elanco is promoting it ahead of a lengthened fall allergy season that Climate Central says stretched an average of 11 days from 1970 to 2025. Zenrelia is a once-daily oral JAK inhibitor for allergic itch in dogs at least 12 months old, and carries a Boxed Warning requiring discontinuation around vaccination due to risk of inadequate immune response.

•25d ago

Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care

Elanco says warming temperatures are turning parasite and dermatology care into a year-round need, with its U.S. Pet Health price gains accelerating quarter-to-date (July and August) versus Q2. The company confirmed U.S. Pet Health remains on track for high-single digit to low double-digit growth in the second half of 2026, after both U.S. and International Pet Health posted 9% organic constant-currency revenue growth in H1 (9% and 15% reported, respectively). Commercial highlights include Credelio Quattro adding roughly 1,100 clinics quarter-to-date, Zenrelia gaining 10 share points in Europe (5x the competitive entrant), and the legacy base portfolio stabilizing from high-single-digit declines to plus-or-minus low-single-digit levels. The release is a promotional mid-quarter update rather than a formal disclosure, but the price acceleration and reaffirmed second-half trajectory read constructively ahead of Q3 results.

•1mo ago

Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility

Elanco completed a 25,000-square-foot expansion of its Elwood, Kansas facility, part of a total $150 million investment to quadruple monoclonal antibody production capacity. The expansion addresses strong demand for recently launched products Befrena and Trutect, with customer demand for Befrena currently running at twice initial expectations. The project includes a new pilot plant and quality lab, with an additional $30 million planned for warehousing through 2028.

•2mo ago

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

Elanco completed the on-time expansion of its Elwood, Kansas manufacturing site, adding 25,000 square feet to increase monoclonal antibody production capacity by more than four times. The project involves a $120 million investment, with an additional $30 million planned through 2028 for a total commitment of $150 million, supporting the delivery of next-generation biologics like Befrena and Trutect. Management highlighted that customer demand for Befrena is currently two times above expectations, with the expanded capacity targeting unconstrained supply levels by early 2027.

•2mo ago

Elanco's CLiK(TM) Extra (Dicyclanil Topical Suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Elanco received Emergency Use Authorization from the FDA for its CLiK Extra wound spray to prevent New World screwworm infestations in livestock and wildlife. The authorization follows the USDA's confirmation of the parasite's reentry into the U.S. in June and adds to Elanco's toolbox of emergency products, which includes Negasunt Powder and Tanidil. CLiK Extra will be available for purchase through standard product channels, while Elanco advises producers to prioritize early detection and intervention to minimize animal injury and prevent the parasite's spread.

•2mo ago

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Elanco Animal Health received FDA Emergency Use Authorization for its CLiK Extra wound spray to prevent New World screwworm infestations in livestock and various wildlife species. The authorization allows the product to be sold through standard channels for application on wounds, though it is explicitly limited to prevention and not treatment of active infestations. This adds to Elanco's emergency response portfolio, which includes Negasunt Powder and Tanidil, both authorized earlier this year to combat the parasite's recent re-entry into the U.S.

•3mo ago

Elanco Animal Health Reports Second Quarter 2026 Results

Elanco reported Q2 revenue of $1.37 billion, up 10% year-over-year, with adjusted EPS growing 31% to $0.34 driven by strong demand in the pet health segment. The company raised its full-year 2026 revenue outlook to $5.09 billion to $5.14 billion and increased adjusted EPS guidance to $1.10 to $1.16, citing faster-than-planned margin expansion. Management highlighted that the net leverage ratio improved to 3.1x adjusted EBITDA, putting the company on track to reach below 3.0x by next year.

•3mo ago

Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Elanco published its 2025 Impact Report, titled 'Leading with Purpose,' detailing the company's progress in animal health innovation, sustainability, and community engagement. The report highlights $892 million in revenue generated from new product innovations in 2025, driven by products like Credelio Quattro and Zenrelia, and outlines a pipeline targeting 5-6 blockbuster approvals by 2031. Operational sustainability efforts supported carbon-reduction interventions for 1.4 million cattle, resulting in 200,000 metric tons of CO2e reductions, while the company recovered over $13 million in counterfeit products to ensure safety. Employee metrics remained strong with an engagement score of 73%, surpassing external benchmarks, and staff contributed 28,000 volunteer hours to non-profit organizations.

•3mo ago

Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Elanco released its 2025 Impact Report, detailing advancements in animal health innovation, sustainability, and corporate responsibility. The company generated $892 million in revenue from new products, led by Credelio Quattro and Zenrelia, and outlined a pipeline with more than $2 billion in potential peak sales. Operational highlights included facilitating 200,000 metric tons of CO₂e reductions for cattle producers and achieving a 73% employee engagement score.

•3mo ago

Credelio Quattro™ Kills Ticks(1) Faster(2) Than Simparica Trio® and NexGard® Plus

New data published in Parasites & Vectors demonstrates that Elanco's Credelio Quattro kills black-legged ticks within 8 hours and lone star ticks within 12 hours, outperforming competitors Simparica Trio and NexGard Plus. The study highlights that Credelio Quattro maintains its rapid speed of kill through the end of the 28-day dosing period, whereas competitors showed performance declines. Dr. Casey Locklear noted that the rapid speed of kill is critical for preventing disease transmission such as Lyme disease, reinforcing the product's value proposition.

•3mo ago

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

New data published in Parasites & Vectors demonstrates that Elanco's Credelio Quattro kills ticks faster than leading competitors Simparica Trio and NexGard Plus. The study found Credelio Quattro significantly reduced black-legged tick infestations within 8 hours and lone star ticks within 12 hours, with no performance drop-off at the end of the 28-day dosing period. This rapid speed of kill supports the product's FDA-approved claim for preventing Lyme disease by killing the primary vector, the black-legged tick, before disease transmission typically occurs.

•3mo ago

Elanco To Launch Elanco Ventures With $25 Million Multi-Year Commitment To Accelerate Innovation in Animal Health

Elanco is launching Elanco Ventures, a dedicated corporate venture capital platform backed by a $25 million multi-year commitment. The fund will focus on early-stage investments in therapeutic advancements and supportive technologies across the animal health sector, with potential expansion into the broader One Health landscape. Launching in late 2026, the platform will be overseen by Eric Steager and leverage partnerships within the One Health Innovation District in Indianapolis, anchored by Elanco and Purdue University.

•4mo ago

Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

Elanco Animal Health announced the launch of Elanco Ventures, a corporate venture capital platform backed by a $25 million multi-year commitment aimed at accelerating innovation in the sector. The platform will prioritize strategic investments in early-stage companies, specifically focusing on Pre-Seed, Seed, and Series A therapeutics and supportive technologies. Elanco Ventures will be overseen by Eric Steager and will leverage partnerships within the One Health Innovation District, which is anchored by Elanco and Purdue University.

•4mo ago

Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs

Elanco received USDA approval for TruCan Ultra Lyme-L4, the first and only 1/2 mL combination vaccine protecting dogs against both Lyme disease and leptospirosis. The product leverages proprietary PureFil Technology to reduce vaccination reactions and minimizes injection volume, addressing a 40% protection gap in Lyme vaccination among at-risk dogs. With Leptospirosis now classified as a core vaccine by AAHA guidelines, the combination format offers a competitive advantage in convenience and compliance. Shipping is expected to begin within 30 days.

•4mo ago

Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

Elanco reaffirms its commitment to supporting U.S. livestock producers and pet owners following the first confirmed case of New World screwworm in U.S. livestock in Texas. The company highlights its portfolio of treatment options, including Negasunt Powder and Tanidil for livestock, and Credelio Quattro-CA1, Credelio CAT, and Credelio for pets, many of which have received Emergency Use Authorizations or conditional approvals from the FDA. CEO Jeff Simmons emphasized the company's 70+ years of experience in mitigating this parasite, positioning Elanco as a key partner for veterinarians and producers in managing this escalating threat.

•5mo ago

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

Elanco has launched Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for treating canine allergic and atopic dermatitis. The product offers a differentiated 6 to 8-week dosing interval, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab, and starts controlling itch within 24 hours. Befrena is Elanco's second USDA-approved monoclonal antibody, joining Trutect, and targets the $1.3 billion U.S. canine dermatology market with a phased launch strategy.

•5mo ago

Elanco Animal Health Reports First Quarter 2026 Results

Elanco reported Q1 2026 revenue of $1.37 billion, up 15% year-over-year, driven by 10% organic constant currency growth and strong performance across its pet health and farm animal segments. The company raised its full-year 2026 guidance, now targeting revenue of $5.01 billion to $5.09 billion and Adjusted EBITDA of $975 million to $1.005 billion, while improving its year-end net leverage ratio target to 3.0x-3.2x. Key product highlights included Zenrelia achieving blockbuster status and Credelio Quattro gaining market share, supported by new retail customer additions and the acquisition of AHV International.

•6mo ago

/C O R R E C T I O N -- Elanco Animal Health/

Elanco Animal Health received Emergency Use Authorization from the FDA and a Section 18 Emergency Exemption from the EPA for Negasunt Powder and Tanidil to combat New World screwworm in livestock. These authorizations allow the immediate use of these products for prevention and treatment, a critical step as the pest has been detected within 62 miles of the U.S. border. Distribution will be managed through the USDA's National Veterinary Stockpile and state officials, expanding Elanco's portfolio of livestock protection solutions alongside its existing Catron IV product.

•6mo ago

Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock

Elanco secured Emergency Use Authorization from the FDA for Negasunt Powder and a Section 18 Emergency Exemption from the EPA for Tanidil to prevent and treat New World screwworm in livestock. The authorizations were granted following confirmed detections of the pest within 62 miles of the U.S. border, ensuring veterinarians and producers have immediate access to treatments through the National Veterinary Stockpile. Elanco also highlighted its existing product Catron IV as a registered solution, positioning its portfolio as a comprehensive defense against the emerging biosecurity threat.

•6mo ago